How should hyperkalemia be managed in a patient on peritoneal dialysis?

Management of Hyperkalemia in Peritoneal Dialysis Patients

In patients on peritoneal dialysis with hyperkalemia, continue PD as the primary treatment modality while addressing reversible factors and optimizing dialysis prescription—PD is equally effective as hemodialysis for managing even severe hyperkalemia (K+ >6.5 mEq/L), with comparable potassium reduction trajectories and clinical outcomes. 1

Acute Severe Hyperkalemia (K+ >6.0 mEq/L or ECG Changes)

For life-threatening hyperkalemia in PD patients, implement immediate stabilization measures while initiating or intensifying PD exchanges:

Immediate Stabilization (First 1-3 minutes)

• IV calcium gluconate or chloride (10 mL of 10%) to stabilize cardiac membranes 2, 3
• Monitor ECG continuously for peaked T waves, prolonged QRS complexes

Intracellular Shift (Within 30-60 minutes)

• IV insulin (10 units) with 50 mL dextrose 2
• Nebulized salbutamol (20 mg in 4 mL) 2
• IV sodium bicarbonate only if concurrent metabolic acidosis present 3

Critical caveat: These measures provide only temporary benefit (1-4 hours) and do not remove total body potassium—rebound hyperkalemia commonly occurs after 2 hours 3. Therefore, definitive potassium removal via PD must be initiated immediately.

Peritoneal Dialysis Management

PD can effectively manage severe hyperkalemia without requiring hemodialysis transfer. 1, 4 A 2025 prospective study demonstrated that PD patients with severe hyperkalemia (K+ >6.5 mEq/L) achieved substantial potassium reduction by Day 1 (from 6.99 to 6.03 mEq/L) with stabilization by Day 5, comparable to hemodialysis outcomes 1.

Intensify PD prescription:

• Increase exchange frequency to continuous cycling or manual exchanges every 2-4 hours 4
• Use standard glucose-based dialysate (potassium-free)
• Average of 45 exchanges during hospitalization achieves adequate control 1
• ED personnel can initiate manual exchanges if trained 4

Chronic/Recurrent Hyperkalemia (K+ 5.0-6.0 mEq/L)

Identify and Address Reversible Factors

Medication review 3:

• NSAIDs, trimethoprim-sulfamethoxazole, beta-blockers
• Calcineurin inhibitors (cyclosporine, tacrolimus)
• Potassium-sparing diuretics
• Do NOT discontinue RAASi unless absolutely necessary—discontinuation increases mortality risk 2

Dietary sources 3:

• Potassium supplements, salt substitutes
• High-potassium fruits (bananas, melons, orange juice)
• Herbal supplements (dandelion, nettle, noni juice, Siberian ginseng)

Volume status 5:

• Episodes of ECF volume depletion decrease residual kidney function and worsen hyperkalemia
• Avoid volume depletion unless necessary for CHF management

Optimize PD Prescription

Increase dialysate potassium removal:

• Increase dwell volumes if tolerated
• Increase number of exchanges per day
• Consider automated PD with more frequent cycling
• Monitor adequacy including potassium removal 6

Dietary Management

Important nuance: Recent evidence challenges strict dietary potassium restriction 7. The 2021 KDIGO conference found limited direct evidence linking dietary potassium intake to serum levels in CKD patients 2. Overly restrictive diets are difficult to maintain, may worsen nutritional status in ESRD patients, and eliminate beneficial plant-based foods 7, 8.

Practical approach:

• Individualized dietary counseling focusing on high-potassium processed foods and supplements
• Avoid blanket restrictions on fruits and vegetables
• Implement continuous quality improvement with monthly 3-day dietary records 6
• This approach reduced hyperkalemia prevalence from 14.3% to 6% at 6 months 6

Potassium Binders

For recurrent hyperkalemia despite optimized PD and dietary measures, consider newer potassium binders 2, 9, 7:

• Sodium zirconium cyclosilicate (SZC) or patiromer
• These agents maintain safe potassium levels and may allow continuation of RAASi therapy 2
• Particularly valuable when RAASi discontinuation would increase cardiovascular mortality risk
• Treatment is likely indefinite unless reversible causes are corrected 9

Avoid older resins (sodium polystyrene sulfonate) in routine management due to limited efficacy and GI complications 3.

Monitoring Strategy

Continuous potassium monitoring is essential 9, 7:

• Check K+ within 1 week after any medication changes affecting potassium homeostasis 2
• More frequent monitoring (weekly to monthly) in high-risk patients with diabetes, heart failure, or history of hyperkalemia 2
• After stabilization with potassium binders, additional monitoring beyond routine comorbidity checks is unnecessary 9

Critical Pitfalls to Avoid

1. Do not automatically transfer PD patients to hemodialysis for hyperkalemia—PD is equally effective even for severe cases 1
2. Do not discontinue RAASi reflexively—this increases mortality risk; instead, treat hyperkalemia and continue RAASi 2, 9
3. Do not rely solely on temporary measures (insulin, beta-agonists)—initiate definitive potassium removal immediately to prevent rebound 3
4. Do not impose overly restrictive diets—this worsens nutritional status without strong evidence of benefit 2, 7
5. Rule out pseudohyperkalemia from hemolysis or poor sampling technique before aggressive treatment 3

Hemodialysis Consideration

Reserve hemodialysis for:

• Oliguria or anuric patients where PD cannot achieve adequate clearance 2
• Resistant acute hyperkalemia despite optimized PD 2
• Catheter dysfunction preventing adequate PD exchanges (occurs in ~11% of patients) 1

The median hospitalization for severe hyperkalemia managed with either modality is 5 days, with similar 12-month mortality (26.8%) 1.